Thirty-day Mortality for Patients with Genitourinary Malignancies Being Treated with Chemotherapy

Clinical Oncology

Volume 21, Issue 9, November 2009, Page 730

National Confidential Enquiry into Patient Outcome and Death (NCEPOD)
For better, for worse?
I.F. Tannock et al.
Docetaxel plus prednisolone or mitoxantrone plus prednisolone for advanced prostate cancer
N Engl J Med
(2004)

A population-based study of prostate cancer chemotherapy
2011, Clinical Oncology
Citation Excerpt :
Many prostate cancer patients are unfit for chemotherapy, the NICE guidance stipulating that a patient must be of good performance status to receive docetaxel [5]. There is evidence to suggest that in this patient group, a poor performance status is associated with higher rates of 30 day mortality after chemotherapy [6]. In addition, some patients choose not to receive chemotherapy, so overall it is uncertain to what extent patients are ‘missing out’ on treatment.
Prospective analysis of 30-day mortality following palliative chemotherapy at a tertiary cancer centre
2018, Cancer Reports
Targeted nanomedicine to treat bone metastasis
2018, Pharmaceutics
Mortality within 30 days of systemic anticancer therapy at a tertiary cancer centre: Assessing the safety and quality of clinical care
2017, New Zealand Medical Journal
Mortality within 30days of receiving systemic anti-cancer therapy at a regional oncology unit: What have we learned?
2012, Asia-Pacific Journal of Clinical Oncology